Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: A pilot study

BMC Pulmonary Medicine

Volumn 15, Issue 1, 2015, Pages

  Kimura, Mai ^a   Tamura, Yuichi ^a   Takei, Makoto ^a   Yamamoto, Tsunehisa ^a   Ono, Tomohiko ^a   Fujita, Jun ^a   Kataoka, Masaharu ^a   Kuwana, Masataka ^b   Satoh, Toru ^c   Fukuda, Keiichi ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NIPPON MEDICAL SCHOOL   (Japan)

^c KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

New treatment option; Phosphodiesterase type 5 inhibitor; Pulmonary arterial hypertension

Indexed keywords

ENDOTHELIN RECEPTOR ANTAGONIST; PROSTANOID; SILDENAFIL; TADALAFIL; AMBRISENTAN; ANTIHYPERTENSIVE AGENT; BERAPROST; BOSENTAN; PHENYLPROPIONIC ACID DERIVATIVE; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; PROSTAGLANDIN; PYRIDAZINE DERIVATIVE; SULFONAMIDE;

6 MINUTE WALK TEST; ADULT; ARTICLE; CLINICAL ARTICLE; DIARRHEA; DRUG TOLERABILITY; EXERCISE TOLERANCE; FEMALE; FUNCTION TEST; HEADACHE; HEART CATHETERIZATION; HEART INDEX; HEMODYNAMIC PARAMETERS; HOT FLUSH; HUMAN; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MIDDLE AGED; PILOT STUDY; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; ANALOGS AND DERIVATIVES; COMBINATION DRUG THERAPY; EXERCISE TEST; HYPERTENSION, PULMONARY; LUNG WEDGE PRESSURE; TREATMENT OUTCOME; VASCULAR RESISTANCE; YOUNG ADULT;

ADULT; ANTIHYPERTENSIVE AGENTS; CARDIAC CATHETERIZATION; DRUG THERAPY, COMBINATION; ENDOTHELIN RECEPTOR ANTAGONISTS; EPOPROSTENOL; EXERCISE TEST; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MIDDLE AGED; PHENYLPROPIONATES; PHOSPHODIESTERASE 5 INHIBITORS; PILOT PROJECTS; PROSTAGLANDINS; PULMONARY WEDGE PRESSURE; PYRIDAZINES; RETROSPECTIVE STUDIES; SILDENAFIL CITRATE; SULFONAMIDES; TADALAFIL; TREATMENT OUTCOME; VASCULAR RESISTANCE; YOUNG ADULT;

EID: 84929332193     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/s12890-015-0037-8     Document Type: Article

References (20)

1. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med. 1995;333:214-21.
2. Archer SL, Djaballah K, Humbert M, Weir KE, Fartoukh M, Dall'ava-Santucci J, et al. Nitric oxide deficiency in fenfluramine- and dexfenfluramine-induced pulmonary hypertension. Am J Respir Crit Care Med. 1998;158:1061-7.
3. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation. 2002;105:2398-403.
4. Sastry BK, Narasimhan C, Reddy NK, Raju BS. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebocontrolled, double-blind, crossover study. J Am Coll Cardiol. 2004;43:1149-53.
5. Galie' N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353:2148-57.
6. Singh T, Rohit M, Grover A, Vijayvergiya R. A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J. 2006;151:851.e1-e5.
7. Galie' N, Brundage BH, Ghofrani H, Oudiz RJ, Simonneau G, Safdar Z, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009;119:2894-903. Tadalafil therapy for pulmonary arterial hypertension.
8. Gabler NB, French B, Strom BL, Palevsky HI, Taichman DB, Kawut SM, et al. Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials. Circulation. 2012;126(3):349-56.
9. Hassoun PM, Nikkho S, Rosenzweig EB, Moreschi G, Lawrence J, Teeter J, et al. Updating clinical endpoint definitions. Pulm Circ. 2013;3(1):206-16.
10. Rubin LJ, Badesch DB, Fleming TR, Galiè N, Simonneau G, Ghofrani HA, et al. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. Chest. 2011;140(5):1274-83.
11. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009;54(1 Suppl):S43-54.
12. Archer SL, Michelakis ED. An evidence-based approach to the management of pulmonary arterial hypertension. Curr Opin Cardiol. 2006;21:385-92.
13. Barst RJ. Updated evidence-based treatment algorithm for pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54 suppl 10:S78-84.
14. Lee SH, Rubin LJ. Current treatment strategies for pulmonary arterial hypertension. J Intern Med. 2005;258:199-215.
15. O'Callaghan DS, Gaine SP. Combination therapy and new types of agents for pulmonary arterial hypertension. Clin Chest Med. 2007;28:169-85.
16. Galiè N, Manes A, Negro L, Palazzini M, Bacchi-Reggiani ML, Branzi A. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J. 2009;30(4):394-403.
17. Dingemanse J, van Giersbergen PLM. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin Pharmacokinet. 2004;43:1089-115.
18. Burgess G, Hoogkamer H, Collings L, Dingemanse J. Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. Eur J Clin Pharmacol. 2008;64(1):43-50.
19. Wrishko RE, Dingemanse J, Yu A, Darstein C, Phillips DL, Mitchell MI. Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects. J Clin Pharmacol. 2008;48(5):610-8.
20. Barst RJ, Ivy DD, Gaitan G, Szatmari A, Rudzinski A, Garcia AE, et al. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. Circulation. 2012;125(2):324-34.